within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA06_Lorazepam;

model Lorazepam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 1.2833333333333335e-06,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.0013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.019,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lorazepam</td></tr><tr><td>ATC code:</td><td>N05BA06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.1</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lorazepam is a short-acting benzodiazepine used primarily to treat anxiety disorders, insomnia, status epilepticus, and as premedication for anesthesia. It has anxiolytic, sedative, anticonvulsant, and muscle relaxant properties. Lorazepam is widely approved and still clinically used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Lebrun-Vignes, B, et al., &amp; Chosidow, O (2001). Clinical pharmacokinetics of mizolastine. <i>Clinical pharmacokinetics</i> 40(7) 501–507. DOI:<a href=\"https://doi.org/10.2165/00003088-200140070-00002\">10.2165/00003088-200140070-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11510627/\">https://pubmed.ncbi.nlm.nih.gov/11510627</a></p></li><li><p>Fleishaker, JC (2000). Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. <i>Clinical pharmacokinetics</i> 39(6) 413–427. DOI:<a href=\"https://doi.org/10.2165/00003088-200039060-00003\">10.2165/00003088-200039060-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11192474/\">https://pubmed.ncbi.nlm.nih.gov/11192474</a></p></li><li><p>Stephen, LJ (2003). Drug treatment of epilepsy in elderly people: focus on valproic Acid. <i>Drugs &amp; aging</i> 20(2) 141–152. DOI:<a href=\"https://doi.org/10.2165/00002512-200320020-00005\">10.2165/00002512-200320020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12534314/\">https://pubmed.ncbi.nlm.nih.gov/12534314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05BA06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lorazepam;
